Lantheus Holdings Inc (LNTH)

Nov 10, 2026

PharmaLogic Holdings Corp. has acquired the CDMO business and radiopharmaceutical manufacturing facility in Springfield, NJ from Lantheus Holdings Inc. This deal expands PharmaLogic's U.S. radiopharmaceutical production capabilities and establishes the first transatlantic CDMO platform dedicated to radioligand therapies. The acquisition includes a long-term supply agreement for Agilera, PharmaLogic's therapeutic CDMO business, to manufacture lutetium Lu 177 dotatate for Lantheus.

Nov 5, 2026

Lantheus Holdings, Inc. announced its approval of the CMS Calendar Year 2027 final rule, which maintains separate payment for diagnostic radiopharmaceuticals and extends Transitional Pass-Through status for PYLARIFY TruVu™ through September 30, 2029. This decision, along with the assignment of a permanent HCPCS code A9613 for PYLARIFY TruVu, aims to improve patient access to advanced diagnostic imaging for prostate cancer and provides reimbursement certainty for hospitals. Lantheus emphasizes the importance of these policies in supporting innovative radiopharmaceutical technologies and informed treatment decisions.

Nov 2, 2026

This article provides an AI-generated analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), indicating a neutral near- and mid-term outlook with a positive long-term bias, but elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels for various time horizons.